CA2488348A1 - Derives de peptide natriuretique de longue duree - Google Patents
Derives de peptide natriuretique de longue duree Download PDFInfo
- Publication number
- CA2488348A1 CA2488348A1 CA002488348A CA2488348A CA2488348A1 CA 2488348 A1 CA2488348 A1 CA 2488348A1 CA 002488348 A CA002488348 A CA 002488348A CA 2488348 A CA2488348 A CA 2488348A CA 2488348 A1 CA2488348 A1 CA 2488348A1
- Authority
- CA
- Canada
- Prior art keywords
- fmoc
- arg
- ser
- gly
- absent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des dérivés de peptide natriurétique (NP) de longue durée. Le dérivé NP comprend un peptide NP et une entité réactive couplée au peptide NP. L'entité réactive peut se lier par covalence avec une fonctionnalité sur un composant sanguin. D'une manière plus spécifique, l'invention concerne des dérivés NP ayant une demi-vie in vivo prolongée ainsi qu'une méthode de traitement des maladies et des troubles cardio-vasculaires, tels que l'insuffisance cardiaque globale décompensée aiguë et l'insuffisance cardiaque globale chronique.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40041302P | 2002-07-31 | 2002-07-31 | |
US40019902P | 2002-07-31 | 2002-07-31 | |
US60/400,199 | 2002-07-31 | ||
US60/400,413 | 2002-07-31 | ||
PCT/CA2003/001097 WO2004011498A2 (fr) | 2002-07-31 | 2003-07-29 | Derives de peptide natriuretique de longue duree |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2488348A1 true CA2488348A1 (fr) | 2004-02-05 |
Family
ID=31191354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002488348A Abandoned CA2488348A1 (fr) | 2002-07-31 | 2003-07-29 | Derives de peptide natriuretique de longue duree |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1530588A2 (fr) |
JP (2) | JP2006514607A (fr) |
AU (1) | AU2003246500A1 (fr) |
CA (1) | CA2488348A1 (fr) |
WO (1) | WO2004011498A2 (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
WO2002066511A2 (fr) | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux |
WO2004022003A2 (fr) | 2002-09-06 | 2004-03-18 | University Of South Florida | Substances et procedes servant a traiter des maladies allergiques |
US8071560B2 (en) | 2004-02-17 | 2011-12-06 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
SG159387A1 (en) | 2002-11-26 | 2010-03-30 | Biocon Ltd In | Modified natriuretic compounds, conjugates, and uses thereof |
US7648962B2 (en) | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
EP1727556A2 (fr) | 2004-02-17 | 2006-12-06 | University Of South Florida | Materiaux et methodes permettant de traiter des troubles inflammatoires et lies a la proliferation cellulaire |
JP4874954B2 (ja) | 2004-04-21 | 2012-02-15 | エノビア ファーマ インコーポレイティド | 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法 |
DE602005026014D1 (de) | 2004-07-15 | 2011-03-03 | Univ Queensland | Proteinartige verbindungen und anwendungen davon |
AU2006222233B2 (en) * | 2005-03-07 | 2011-05-12 | Mondobiotech Ag | Formulation for aviptadil |
WO2006108686A2 (fr) * | 2005-04-14 | 2006-10-19 | Aic | Agonistes bnp |
WO2007041645A2 (fr) * | 2005-10-03 | 2007-04-12 | Scios Inc. | Forme oxydee du bnp humain |
JP5010913B2 (ja) * | 2006-12-31 | 2012-08-29 | 寿子 小出 | 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法 |
KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
WO2008154226A1 (fr) * | 2007-06-06 | 2008-12-18 | Boehringer Ingelheim International Gmbh | Protéines de fusion natriurétiques |
AU2008274845A1 (en) * | 2007-07-06 | 2009-01-15 | Theratechnologies Inc. | Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury |
WO2012013597A1 (fr) | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Substances et utilisation desdites substances pour influer sur les récepteurs peptidiques natriurétiques |
DE102010032482A1 (de) | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung |
WO2012088608A1 (fr) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation |
CN103402534B (zh) * | 2011-02-23 | 2016-10-12 | 麦德林制药私人有限公司 | 用于治疗充血性心力衰竭的治疗方法 |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
CN102286092B (zh) | 2011-09-14 | 2014-01-01 | 深圳翰宇药业股份有限公司 | 利拉鲁肽的固相合成方法 |
EP2849567B1 (fr) | 2012-05-17 | 2022-03-23 | Extend Biosciences, Inc. | Véhicules destinés à améliorer l'administration des médicaments |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2016007873A1 (fr) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions et méthodes de traitement de la craniosynostose |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
CA2964463C (fr) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Conjugues de vitamine d therapeutiques |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
US10449236B2 (en) | 2014-12-05 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
AU2016272282A1 (en) * | 2015-05-29 | 2018-01-25 | Igisu Co., Ltd. | Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide |
MX2018002121A (es) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Elaboracion de fosfatasas alcalinas. |
WO2017058822A1 (fr) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp) |
JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
EP3436052A4 (fr) | 2016-04-01 | 2019-10-09 | Alexion Pharmaceuticals, Inc. | Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
EP3464573A4 (fr) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | Impact du métal sur la production des phosphatases alcalines |
WO2018035420A1 (fr) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Procédés de traitement de la trachéobronchomalacie |
JP2020512363A (ja) | 2017-03-31 | 2020-04-23 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 成人及び青年における低ホスファターゼ症(hpp)を治療する方法 |
EP3773684A1 (fr) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Production de glycoprotéines |
US20240174727A1 (en) | 2022-10-21 | 2024-05-30 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
CN116284329B (zh) * | 2023-04-28 | 2023-12-08 | 成都奥达生物科技有限公司 | 一种长效利钠肽化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3042782B2 (ja) * | 1985-11-05 | 2000-05-22 | サイオス インコーポレイテッド | 心房性ナトリウム尿排泄亢進ペプチド類似化合物 |
EP0223143A3 (fr) * | 1985-11-05 | 1989-04-12 | California Biotechnology, Inc. | Analogues de peptides atriaux natriurétiques |
GR1001018B (el) * | 1989-05-24 | 1993-03-31 | Abbott Lab | Μεθοδος παρασκευης προδρομικων πεπτικων παραγωγων. |
WO2000070665A2 (fr) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Peptides antiangiogeniques durables |
CA2373680C (fr) * | 1999-05-17 | 2008-07-29 | Conjuchem Inc. | Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins |
WO2001017568A2 (fr) * | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Diffusion pulmonaire permettant la bioconjugaison |
-
2003
- 2003-07-29 JP JP2004523679A patent/JP2006514607A/ja active Pending
- 2003-07-29 AU AU2003246500A patent/AU2003246500A1/en not_active Abandoned
- 2003-07-29 EP EP03771007A patent/EP1530588A2/fr not_active Ceased
- 2003-07-29 CA CA002488348A patent/CA2488348A1/fr not_active Abandoned
- 2003-07-29 WO PCT/CA2003/001097 patent/WO2004011498A2/fr active Application Filing
-
2009
- 2009-12-01 JP JP2009273992A patent/JP2010047614A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1530588A2 (fr) | 2005-05-18 |
AU2003246500A1 (en) | 2004-02-16 |
JP2010047614A (ja) | 2010-03-04 |
JP2006514607A (ja) | 2006-05-11 |
WO2004011498A2 (fr) | 2004-02-05 |
WO2004011498A3 (fr) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040266673A1 (en) | Long lasting natriuretic peptide derivatives | |
CA2488348A1 (fr) | Derives de peptide natriuretique de longue duree | |
US7112567B2 (en) | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders | |
US7268113B2 (en) | Long lasting growth hormone releasing factor derivatives | |
US6593295B2 (en) | Long lasting insulinotropic peptides | |
US8080516B2 (en) | Long lasting synthetic exendin-4 peptide conjugates | |
US7906482B2 (en) | Anti-obesity agents | |
AU2002233089A1 (en) | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders | |
AU2002233082A1 (en) | Long lasting growth hormone releasing factor derivatives | |
ZA200106676B (en) | Long lasting insulinotropic peptides. | |
AU2005218012A1 (en) | Long lasting growth hormone releasing factor derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |